Assessment of the Risk of Trombosis in Patients With Atrial Fibrillation and Concomitant Arterial Hypertension After Experiencing the Coronavirus Disease (Covid-19)

Objective: Determine the risk of the probability of thrombosis according to the CHA2DS2-VASc scale in patients with AF and arterial hypertension after suffering from COVID-19. Design and method: The main part of the study consisted of 116 patients (pts) with AF aged 63.8 ± 0.6 years who from 1 to 12 months ago (5.1 ± 0.2 months on average) were infected with COVID-19. Group 1 (G1) 80 pts (69%) who had AF before CI. Group 2 (G2) 36 pts (31%) it appeared after the transferred CI. A control group (CG) 49 pts with AF who did not have a history of COVID-19 the average age was 59.0 ± 0,6 years. Results: Among AF patients who experienced COVID-19, compared with patients in the control group, which included patients with AF but no history of COVID-19 infection, more people had a CHA2DS2-VASc score of 3 or greater, a high risk of thrombosis. Patients in the main group compared to the control group had a higher risk of thrombosis (70.7% vs. 55.1%, p < 0.001). This applies to patients who developed AF after COVID-19 (G1), as well as those patients who had AF before the infection of COVID-19 (72.2% vs. 55.1%, p < 0.001). Conclusions: Patients in whom AF and concomitant hypertension appeared after COVID-19 or this infection worsened the course of the arrhythmia were characterized by a higher risk of thrombosis compared to patients with AF without a history of COVID-19 infection.